Freeline® is a clinical – stage biotech company focused on the development and commercialisation of gene therapies for bleeding and other debilitating disorders based on a next-generation AAV gene therapy platform developed by Amit Nathwani, Professor of Haematology at UCL and CSO of Freeline.
The company is rapidly advancing several programs simultaneously by building a state-of-the-art manufacturing platform for AAV. Established and funded by Syncona, Freeline is based at the Stevenage Bioscience Catalyst (SBC) just north of London and also has facilities in Munich, Germany. The SBC is a national and European hub of cell and gene therapy development, and the Catapult Cell and Gene Therapy manufacturing facility will open there later this year.
The ambition of the growing company and the pace of activities in an intensely competitive field have given rise to this appointment of a second in-house patent attorney, to be based in Stevenage.
This is a fantastic opportunity for a commercially- oriented attorney to join and make a real impact every day at a critical period in the company’s trajectory, in one of the hottest fields in medicine. In doing so the successful candidate will gain a first-hand insight into the working of a 21st-century biotech company and become an expert in patenting cutting-edge gene therapies.